サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1542740

血漿分画の世界市場

Plasma Fractionation

出版日
ページ情報
英文 245 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
血漿分画の世界市場
出版日: 2024年08月28日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 245 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

血漿分画の世界市場は2030年までに407億米ドルに達する見込み

2023年に285億米ドルと推定される血漿分画の世界市場は、分析期間2023-2030年にCAGR 5.2%で成長し、2030年には407億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである免疫グロブリンは、CAGR 6.6%を記録し、分析期間終了時には148億米ドルに達すると予測されます。アルブミン分野の成長率は、分析期間中CAGR 4.4%と推定されます。

米国市場は76億米ドルと推定、中国はCAGR 4.9％で成長予測

米国の血漿分画市場は2023年に76億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに64億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは4.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.9%と4.2%と予測されています。欧州では、ドイツがCAGR 3.8%で成長すると予測されています。

世界の血漿分画市場- 主要動向と促進要因のまとめ

重要なタンパク質の活用血漿分画のプロセス

血漿分画は、血漿からさまざまな成分を分離・精製するための高度なバイオテクノロジープロセスです。血液の液体部分である血漿には、様々なタンパク質や治療に不可欠なその他の物質が含まれています。分画プロセスは、献血による血漿の採取から始まる。採取された血漿は、遠心分離、ろ過、クロマトグラフィーなどの一連の工程を経て、特定のタンパク質が分離されます。アルブミン、免疫グロブリン、凝固因子などのこれらのタンパク質は、治療用に精製、濃縮されます。分画プロセスの各段階は、最終製品の純度、有効性、安全性を確保するために慎重に管理されており、免疫不全や出血性疾患からショックや外傷に至るまで、さまざまな病状の治療に使用されています。

血漿由来製品は医療でどのように利用されているか？

血漿由来製品は現代医療において重要な役割を果たしており、様々な疾患に対して救命治療を提供しています。アルブミンは、血漿分画を通して分離される主要なタンパク質の一つで、血液量と血圧の維持を助けることにより、重度の火傷、肝疾患、低アルブミン血症の患者の治療に使用されます。免疫グロブリン（抗体）は、免疫不全や自己免疫疾患の治療に不可欠です。これらは患者に受動免疫を提供し、感染症と闘う能力を高める。血液凝固第VIII因子や血液凝固第IX因子などの血液凝固因子は、血液凝固に障害のある遺伝性疾患である血友病患者にとって極めて重要です。これらの製品は出血エピソードの予防と制御に役立ち、血友病患者のQOLを著しく向上させる。血漿由来製剤の多様な用途は、広範な医療ニーズに対応し、患者ケアを向上させる上で、その重要性を裏付けています。

血漿分画技術の動向は？

血漿分画業界は、技術の進歩と血漿タンパク質の理解の深まりにより、絶えず進化しています。重要な動向の一つは、血漿由来製品の収量と純度を高める高度なクロマトグラフィーやろ過法などの精製技術の向上です。もう一つのトレンドは組換えDNA技術の開発であり、これによって特定の血漿タンパク質を実験室内で生産できるようになり、血漿提供への依存度が下がり、これらの重要な治療法の利用可能性が高まっています。自動化とデジタル技術の統合もまた、血漿分画を変革し、より効率的でスケーラブルな生産プロセスを可能にしています。さらに、新たな疾患や病態の治療を含め、血漿由来製品の治療応用範囲の拡大にも注目が集まっています。このような技術の進歩と革新的なアプローチが血漿分画の将来を形成し、治療をより効果的で身近なものにしています。

血漿分画市場の成長を促進する要因は？

血漿分画市場の成長にはいくつかの要因があり、それぞれが血漿由来の治療に対する需要の増加を反映しています。血友病や原発性免疫不全症などの慢性疾患や遺伝性疾患の有病率の上昇は、これらの疾患が血漿由来製剤による定期的かつ長期的な治療を必要とすることから、重要な促進要因となっています。分画プロセスにおける技術の進歩や遺伝子組換え療法の開発は、生産の効率性と拡張性を高め、需要の増加に対応しています。新興国市場におけるヘルスケアインフラの拡充は、血漿由来療法へのアクセスを増加させ、市場の成長に寄与しています。さらに、世界の高齢化により、肝疾患や免疫不全などの加齢に関連した疾患の治療需要が高まっています。患者の転帰を改善することが重視され、血漿タンパク質の新たな治療用途に関する研究が進められていることも、市場の拡大をさらに後押ししています。これらの要因が総合的に血漿分画市場の堅調な成長を保証し、現代ヘルスケアと治療開発における重要な役割を浮き彫りにしています。

調査対象企業の例（全47件）

  • Bio Products Laboratory Ltd.
  • Biotest AG
  • China Biologic Products, Inc.
  • CSL Limited
  • Green Cross Corporation
  • Grifols SA
  • Japan Blood Products Organization
  • Kedrion SpA
  • LFB SA
  • Octapharma AG
  • Sanquin
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shire PLC

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP14015

Global Plasma Fractionation Market to Reach US$40.7 Billion by 2030

The global market for Plasma Fractionation estimated at US$28.5 Billion in the year 2023, is expected to reach US$40.7 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2023-2030. Immunoglobulins, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$14.8 Billion by the end of the analysis period. Growth in the Albumin segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.6 Billion While China is Forecast to Grow at 4.9% CAGR

The Plasma Fractionation market in the U.S. is estimated at US$7.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$6.4 Billion by the year 2030 trailing a CAGR of 4.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.9% and 4.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Global Plasma Fractionation Market - Key Trends and Drivers Summarized

Harnessing Vital Proteins: The Process of Plasma Fractionation

Plasma fractionation is a sophisticated biotechnological process used to separate and purify different components from blood plasma. Plasma, the liquid portion of blood, contains a variety of proteins and other substances essential for medical treatments. The fractionation process begins with the collection of plasma through donation. Once collected, the plasma undergoes a series of steps, including centrifugation, filtration, and chromatography, to isolate specific proteins. These proteins, such as albumin, immunoglobulins, and clotting factors, are then purified and concentrated for therapeutic use. Each step in the fractionation process is carefully controlled to ensure the purity, efficacy, and safety of the final products, which are used to treat a range of medical conditions, from immune deficiencies and bleeding disorders to shock and trauma.

How Are Plasma-Derived Products Utilized in Medicine?

Plasma-derived products play a critical role in modern medicine, offering life-saving treatments for various conditions. Albumin, one of the major proteins isolated through plasma fractionation, is used to treat patients with severe burns, liver diseases, and hypoalbuminemia by helping maintain blood volume and pressure. Immunoglobulins, or antibodies, are essential for treating immune deficiencies and autoimmune diseases. They provide passive immunity to patients, enhancing their ability to fight infections. Clotting factors, such as Factor VIII and Factor IX, are crucial for patients with hemophilia, a genetic disorder that impairs blood clotting. These products help prevent and control bleeding episodes, significantly improving the quality of life for hemophilia patients. The diverse applications of plasma-derived products underscore their importance in addressing a wide range of medical needs and enhancing patient care.

What Are the Current Trends in Plasma Fractionation Technology?

The plasma fractionation industry is continuously evolving, driven by advancements in technology and a growing understanding of plasma proteins. One significant trend is the improvement in purification techniques, such as advanced chromatography and filtration methods, which enhance the yield and purity of plasma-derived products. Another trend is the development of recombinant DNA technology, which allows for the production of certain plasma proteins in a laboratory setting, reducing dependence on plasma donations and increasing the availability of these critical therapies. The integration of automation and digital technologies is also transforming plasma fractionation, enabling more efficient and scalable production processes. Additionally, there is a growing focus on expanding the range of therapeutic applications for plasma-derived products, including the treatment of emerging diseases and conditions. These technological advancements and innovative approaches are shaping the future of plasma fractionation, making therapies more effective and accessible.

What Factors Are Driving the Growth in the Plasma Fractionation Market?

The growth in the plasma fractionation market is driven by several factors, each reflecting the increasing demand for plasma-derived therapies. The rising prevalence of chronic diseases and genetic disorders, such as hemophilia and primary immune deficiencies, is a significant driver, as these conditions require regular and long-term treatment with plasma-derived products. Technological advancements in fractionation processes and the development of recombinant therapies are enhancing the efficiency and scalability of production, meeting the growing demand. The expansion of healthcare infrastructure in developing regions is increasing access to plasma-derived therapies, contributing to market growth. Additionally, the aging global population is driving demand for treatments for age-related conditions, such as liver disease and immunodeficiencies. The emphasis on improving patient outcomes and the ongoing research into new therapeutic applications for plasma proteins further support market expansion. These factors collectively ensure robust growth in the plasma fractionation market, highlighting its critical role in modern healthcare and therapeutic development.

Select Competitors (Total 47 Featured) -

  • Bio Products Laboratory Ltd.
  • Biotest AG
  • China Biologic Products, Inc.
  • CSL Limited
  • Green Cross Corporation
  • Grifols SA
  • Japan Blood Products Organization
  • Kedrion SpA
  • LFB SA
  • Octapharma AG
  • Sanquin
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shire PLC

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Plasma Fractionation: Overview & Outlook
    • Plasma Fractionation - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Intravenous Immunoglobulin Products Gain Traction
    • Rising Incidence of Respiratory Diseases: Major Driver
    • Growing Prevalence of Bleeding Disorders Bodes Well
    • Rise in AATD Cases Steers Demand
    • Advancements in Plasma Collection Technology Favor Growth
    • Recombinant Technology: Key Challenge
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Plasma Fractionation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Plasma Fractionation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Plasma Fractionation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Coagulation Factor Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Coagulation Factor Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Coagulation Factor Concentrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Albumin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Albumin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Albumin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Protease Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Protease Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Protease Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Clinical Research Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Clinical Research Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Clinical Research Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Academic Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 25: World Plasma Fractionation Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Immunoglobulins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Immunoglobulins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Immunoglobulins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Immunology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Pulmonology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Pulmonology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: World 16-Year Perspective for Pulmonology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Plasma Fractionation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Plasma Fractionation by Product - Percentage Breakdown of Value Sales for Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products for the Years 2014, 2024 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Plasma Fractionation by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes for the Years 2014, 2024 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: USA 16-Year Perspective for Plasma Fractionation by Application - Percentage Breakdown of Value Sales for Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Plasma Fractionation by Product - Percentage Breakdown of Value Sales for Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products for the Years 2014, 2024 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for Plasma Fractionation by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes for the Years 2014, 2024 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Canada 16-Year Perspective for Plasma Fractionation by Application - Percentage Breakdown of Value Sales for Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications for the Years 2014, 2024 & 2030
  • JAPAN
    • Plasma Fractionation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Plasma Fractionation by Product - Percentage Breakdown of Value Sales for Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products for the Years 2014, 2024 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Japan 16-Year Perspective for Plasma Fractionation by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes for the Years 2014, 2024 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Japan 16-Year Perspective for Plasma Fractionation by Application - Percentage Breakdown of Value Sales for Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications for the Years 2014, 2024 & 2030
  • CHINA
    • Plasma Fractionation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 74: China Recent Past, Current & Future Analysis for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: China 16-Year Perspective for Plasma Fractionation by Product - Percentage Breakdown of Value Sales for Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products for the Years 2014, 2024 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: China 16-Year Perspective for Plasma Fractionation by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes for the Years 2014, 2024 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: China 16-Year Perspective for Plasma Fractionation by Application - Percentage Breakdown of Value Sales for Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications for the Years 2014, 2024 & 2030
  • EUROPE
    • Plasma Fractionation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Plasma Fractionation by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Plasma Fractionation by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Plasma Fractionation by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Plasma Fractionation by Product - Percentage Breakdown of Value Sales for Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products for the Years 2014, 2024 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Europe 16-Year Perspective for Plasma Fractionation by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes for the Years 2014, 2024 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Europe 16-Year Perspective for Plasma Fractionation by Application - Percentage Breakdown of Value Sales for Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications for the Years 2014, 2024 & 2030
  • FRANCE
    • Plasma Fractionation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 95: France Recent Past, Current & Future Analysis for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: France 16-Year Perspective for Plasma Fractionation by Product - Percentage Breakdown of Value Sales for Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products for the Years 2014, 2024 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: France 16-Year Perspective for Plasma Fractionation by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes for the Years 2014, 2024 & 2030
    • TABLE 101: France Recent Past, Current & Future Analysis for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: France 16-Year Perspective for Plasma Fractionation by Application - Percentage Breakdown of Value Sales for Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications for the Years 2014, 2024 & 2030
  • GERMANY
    • Plasma Fractionation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Plasma Fractionation by Product - Percentage Breakdown of Value Sales for Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products for the Years 2014, 2024 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Germany 16-Year Perspective for Plasma Fractionation by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes for the Years 2014, 2024 & 2030
    • TABLE 110: Germany Recent Past, Current & Future Analysis for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Germany 16-Year Perspective for Plasma Fractionation by Application - Percentage Breakdown of Value Sales for Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Plasma Fractionation by Product - Percentage Breakdown of Value Sales for Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products for the Years 2014, 2024 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Italy 16-Year Perspective for Plasma Fractionation by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes for the Years 2014, 2024 & 2030
    • TABLE 119: Italy Recent Past, Current & Future Analysis for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Italy Historic Review for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Italy 16-Year Perspective for Plasma Fractionation by Application - Percentage Breakdown of Value Sales for Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Plasma Fractionation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 122: UK Recent Past, Current & Future Analysis for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Plasma Fractionation by Product - Percentage Breakdown of Value Sales for Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products for the Years 2014, 2024 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: UK 16-Year Perspective for Plasma Fractionation by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes for the Years 2014, 2024 & 2030
    • TABLE 128: UK Recent Past, Current & Future Analysis for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: UK Historic Review for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: UK 16-Year Perspective for Plasma Fractionation by Application - Percentage Breakdown of Value Sales for Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Europe 16-Year Perspective for Plasma Fractionation by Product - Percentage Breakdown of Value Sales for Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for Plasma Fractionation by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Plasma Fractionation by Application - Percentage Breakdown of Value Sales for Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Plasma Fractionation Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Asia-Pacific 16-Year Perspective for Plasma Fractionation by Product - Percentage Breakdown of Value Sales for Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products for the Years 2014, 2024 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for Plasma Fractionation by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes for the Years 2014, 2024 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Plasma Fractionation by Application - Percentage Breakdown of Value Sales for Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 149: Rest of World Recent Past, Current & Future Analysis for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Rest of World Historic Review for Plasma Fractionation by Product - Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Rest of World 16-Year Perspective for Plasma Fractionation by Product - Percentage Breakdown of Value Sales for Immunoglobulins, Albumin, Coagulation Factor Concentrates, Protease Inhibitors and Other Products for the Years 2014, 2024 & 2030
    • TABLE 152: Rest of World Recent Past, Current & Future Analysis for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Rest of World Historic Review for Plasma Fractionation by End-Use - Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Rest of World 16-Year Perspective for Plasma Fractionation by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Clinical Research Laboratories and Academic Institutes for the Years 2014, 2024 & 2030
    • TABLE 155: Rest of World Recent Past, Current & Future Analysis for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of World Historic Review for Plasma Fractionation by Application - Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of World 16-Year Perspective for Plasma Fractionation by Application - Percentage Breakdown of Value Sales for Neurology, Immunology, Hematology, Oncology, Pulmonology and Other Applications for the Years 2014, 2024 & 2030

IV. COMPETITION